Washington, March 5
COVID-19 antibody-based drugs and vaccines developed so far may become less effective as new variants of the novel coronavirus spread widely, according to a new study.
The resear
Synthetic Biologics Reports 2020 Year End Operational Highlights and Financial Results Announced Washington University Has Begun Screening Patients for Enrollment in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients Reports $72.6M of Cash on Hand to Fund Clinical Programs and Extend Operations into 2023 Conference Call Today at 4:30 p.m. (ET)
News provided by
Share this article
Share this article
ROCKVILLE, Md., March 4, 2021 /PRNewswire/ Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today provided a clinical programs update and reported financial results for the year ended December 31, 2020.
Radiology and Radiation Oncology | Imaging Technology News itnonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itnonline.com Daily Mail and Mail on Sunday newspapers.
New evidence COVID-19 antibodies, vaccines less effective against variants – Washington University School of Medicine in St Louis wustl.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wustl.edu Daily Mail and Mail on Sunday newspapers.
The emergence of variants of the new coronavirus has raised concern that vaccines and treatments that were developed based on previous strains may not work as robustly.